Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187006 | 0.85 | KDM4E (0.49) | KDM4EALDH1A1USP2LMNAMAPT | |
| SCHEMBL31125095 | 0.84 | KDM4E (0.52) | KDM4EALDH1A1USP2LMNAMAPT | |
| SCHEMBL19742421 | 0.82 | KDM4E (0.46) | KDM4EALDH1A1USP2LMNAMAPT | |
| SCHEMBL8690047 | 0.82 | ALDH1A1 (0.46) | KDM4EALDH1A1USP2LMNAMAPT | |
| SCHEMBL8701677 | 0.82 | PRKCI (0.40) | KDM4EALDH1A1USP2MAPTPOLB | |
| SCHEMBL14394001 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1USP2LMNAMAPT | |
| SCHEMBL13167760 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1USP2LMNAMAPT | |
| SCHEMBL24225891 | 0.79 | KDM4E (0.47) | KDM4EALDH1A1USP2LMNAMAPT | |
| SCHEMBL18179359 | 0.78 | CYP2A6 (0.48) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL23018392 | 0.78 | CYP2A6 (0.48) | ALDH1A1ARCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2513095-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | WYETH (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009120826-A1 | 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | WYETH (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270363-A1 | 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof | SEC63, SEC62, SEC22B | KDM4E 3799/4885ALDH1A1 2705/4885USP2 918/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | KDM4E 3390/4885ALDH1A1 2667/4885USP2 1326/4885 |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | KDM4E 4290/4885ALDH1A1 2182/4885USP2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.